Ondansetron is indicated for the prevention and treatment of chemo- and radiotherapy induced nausea and vomiting (CINV and RINV), and for the prevention and treatment of post-operative nausea and vomiting (PONV).
Has been Developed by APR in cooperation with MonoSol Rx for the USA market and Labtec TESA outside USA respectively. The ODF technology aims to GET around administration problems of the drug and improve patient compliance.
* SETOFILM and the SETOFILM logo are registered trademarks of APR Applied Pharma s.a., exclusively licensed to the Norgine group of companies in the EU.
Ondissolve ODF logo is a registered trademark of Takeda Canada, exclusively licensed in Canada.
Zuplenz logo is a registered trademark of Galena Biopharma inc, exclusively licensed in USA.